Showing results (61-70 of 95) with videos related to
Sort By:
Pageof 10
Arzneimittel-Forschung|February 1, 1987
Plasma levels and pharmacokinetics of single and multiple dose of tetrazepam in healthy volunteersH Bun, F Philip, Y Berger, et al.Thrombosis and Haemostasis|April 1, 1995
Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)F Collignon, A Frydman, H Caplain, et al.The Journal of Clinical Investigation|July 1, 1994
Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reactionT Guyon, P Levasseur, F Truffault, et al.Seminars in Thrombosis and Hemostasis|August 10, 1999
Clopidogrel bioavailability: absence of influence of food or antacidsJ McEwen, G Strauch, P Perles, et al.European Journal of Clinical Pharmacology|January 1, 1996
Multiple dose pharmacokinetics of tiludronate in healthy volunteersH R Schwietert, P A Peeters, J Dingemanse, et al.The Journal of Pediatrics|January 1, 1990
Seizures in relation to shunt dysfunction in children with meningomyeloceleC H Hack, B G Enrile, J F Donat, et al.Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society|June 5, 2007
Pattern-induced negative occipital potentials (PINOP)Kurupath Radhakrishnan, Ashakiran J Sunku, Jane F Donat, et al.Neurology|January 1, 1984
Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravisS Berrih, E Morel, C Gaud, et al.Seminars in Thrombosis and Hemostasis|August 10, 1999
Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interactionP A Peeters, H J Crijns, W J Tamminga, et al.Archives Francaises De Pediatrie|December 1, 1989
[The accelerated phase of Chediak-Higashi syndrome]M Bejaoui, F Veber, D Girault, et al.Pageof 10